Bioventus Inc Cl A (BVS) Stock Price, Quote & News

Company Profile

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise of various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain. It also offers precision bone resection for pat...

Industry: Medical Devices

Sector: Healthcare

Phone: 919 474 6700

Website: www.bioventus.com

Address:

4721 Emperor Boulevard, Suite 100, Durham, United States

MrTicker Jul. 30 at 2:33 PM

$BVS 10:31 AM EDT, 07/30/2025 (MT Newswires) -- Bioventus(BVS) said Wednesday that the US Food and Drug Administration has given 510(k) clearances for TalisMann and StimTrial, the company's peripheral nerve stimulation, or PNS, devices for chronic pain management. TalisMann targets deeper, larger nerves and is designed to provide long-term relief from chronic nerve pain. StimTrial allows doctors to test how patients respond to PNS therapy before starting full treatment, the company said. The company added that it expects to begin a limited US launch of the devices during the third quarter, with a wider release in early 2026.

0 · Reply

MrTicker Jul. 30 at 2:06 PM

$BVS volume slowly picking up.. about to break through $7+ on news

0 · Reply

BigSqueezeComing Jul. 30 at 11:48 AM

$BVS MarketBeat (4 analysts): $13.75 average, ranging from $12.00 to $15.00, implying approximately 110% upside from the $6.53 share price as of July 28, 2025 .

0 · Reply

BigSqueezeComing Jul. 30 at 11:47 AM

$BVS The peripheral nerve stimulation market is growing over 20% annually and is projected to exceed $500 million by 2029

0 · Reply

MrTicker Jul. 30 at 11:46 AM

$BVS excellent news...word not out yet

0 · Reply

BigSqueezeComing Jul. 30 at 11:45 AM

$BVS Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products By Bioventus, Inc. | July 30, 2025, 7:30 AM

0 · Reply

StockRedBaron Jul. 30 at 11:42 AM

$BVS WOW! So HUGE for us!...WHY all the Insider Buying in June!! https://finance.yahoo.com/news/bioventus-receives-fda-510-k-113000698.html

0 · Reply

MrTicker Jul. 30 at 11:39 AM

$BVS These two clearances mark an important step forward for Bioventus(BVS) and represent a substantial growth opportunity as the Company looks to expand in the PNS market, which is currently estimated to be growing above 20 percent annually and expected to exceed $500 million by 2029. With TalisMann™ and StimTrial™ now FDA-cleared, Bioventus(BVS) offers a comprehensive PNS portfolio that empowers physicians to potentially treat a broader spectrum of patients—from initial assessment to long-term therapy—with greater confidence and flexibility. This development also reinforces the Company's commitment to delivering non-opioid, minimally invasive therapies designed to address real-world clinical needs.

0 · Reply

MrTicker Jul. 30 at 11:33 AM

$BVS Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products GLOBENEWSWIRE 6:30 AM ET 7/30/2025

0 · Reply

swingingtech Jun. 20 at 12:08 PM

$FHLC $BVS $BCRX $AVBP https://wallstreetwaves.com/peek-under-the-hood-fhlc-has-21-upside/

0 · Reply

Bioventus to Present at the Canaccord Genuity 45th Annual Global Growth Conference

Aug 7, 2025, 12:58 AM EDT - 6 days ago

Bioventus Inc. (BVS) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 7:00 AM EDT - 7 days ago

Bioventus Reports Second Quarter Financial Results

Aug 4, 2025, 8:00 AM EDT - 9 days ago

Bioventus Enters into a New $400 Million Senior Secured Credit Agreement Lowering Interest Expense and Providing Increased Liquidity

Jul 30, 2025, 7:30 AM EDT - 14 days ago

Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products

Jul 29, 2025, 4:15 PM EDT - 14 days ago

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025

May 6, 2025, 4:55 PM EDT - 3 months ago

Bioventus Inc. (BVS) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 3 months ago

Bioventus Reports First Quarter Financial Results

Apr 28, 2025, 8:00 AM EDT - 3 months ago

Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

Mar 11, 2025, 2:31 PM EDT - 5 months ago

Bioventus Inc. (BVS) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 11:17 AM EDT - 5 months ago

Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million

Mar 11, 2025, 7:30 AM EDT - 5 months ago

Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results

Feb 28, 2025, 7:30 AM EST - 5 months ago

Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

Jan 2, 2025, 8:00 AM EST - 7 months ago

Bioventus Completes Divestiture of its Advanced Rehabilitation Business to Accelmed Partners

Nov 5, 2024, 12:26 PM EST - 10 months ago

Bioventus Inc. (BVS) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 7:30 AM EST - 10 months ago

Bioventus Reports Third Quarter Financial Results

Oct 29, 2024, 7:30 AM EDT - 10 months ago

Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

Aug 21, 2024, 7:37 AM EDT - 1 year ago

Executives Buying W. P. Carey And 2 Other Stocks

WPC GWRS

Aug 12, 2024, 11:01 AM EDT - 1 year ago

Healing Numbers, Hurting Valuation: Bioventus' Mixed Bag In Q2 2024

Aug 11, 2024, 1:45 PM EDT - 1 year ago

Bioventus Inc. (BVS) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 4:15 PM EDT - 1 year ago

Bioventus to Present at the Canaccord Genuity 44th Annual Global Growth Conference

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Bioventus to Report Second Quarter of Fiscal Year 2024 Financial Results on August 6, 2024

May 7, 2024, 12:02 PM EDT - 1 year ago

Bioventus, Inc. (BVS) Q1 2024 Earnings Call Transcript

Apr 29, 2024, 7:30 AM EDT - 1 year ago

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

Mar 12, 2024, 11:00 AM EDT - 1 year ago

Bioventus Inc. (BVS) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:30 AM EDT - 1 year ago

Bioventus Announces Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 8:00 AM EST - 1 year ago

Bioventus to Report Fourth Quarter of Fiscal Year 2023 Financial Results on March 12, 2024

Jan 24, 2024, 2:00 PM EST - 1 year ago

Bioventus: Bullish On Path To Profitability

Jan 18, 2024, 4:15 PM EST - 1 year ago

Bioventus Enters into an Amendment with its Credit Agreement Lenders to Enhance Financial and Operational Flexibility

Jan 12, 2024, 4:15 PM EST - 1 year ago

Bioventus Announces Inducement Equity to President and Chief Executive Officer Robert Claypoole

Dec 19, 2023, 4:30 PM EST - 1 year ago

Bioventus Names Robert Claypoole as President and Chief Executive Officer

Dec 6, 2023, 8:00 AM EST - 1 year ago

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

Nov 12, 2023, 12:55 AM EST - 1 year ago

Bioventus Inc. (BVS) Q3 2023 Earnings Call Transcript

Nov 7, 2023, 7:00 AM EST - 1 year ago

Bioventus Reports Third Quarter Financial Results; Raises Full Year 2023 Financial Guidance

Oct 31, 2023, 7:00 AM EDT - 1 year ago

Bioventus to Report Third Quarter of Fiscal Year 2023 Financial Results on November 7, 2023

Oct 11, 2023, 5:44 PM EDT - 1 year ago

Bioventus Stock: Improving Outlook Keeps It Interesting

Sep 19, 2023, 9:52 PM EDT - 2 years ago

Bioventus to Present at the Cantor Global Healthcare Conference

Sep 6, 2023, 4:30 PM EDT - 2 years ago

Bioventus to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

Aug 12, 2023, 1:56 PM EDT - 2 years ago

Bioventus Inc. (BVS) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 7:30 AM EDT - 2 years ago

Bioventus Reports Second Quarter Financial Results; Introduces Full Year 2023 Financial Guidance

Aug 4, 2023, 8:30 AM EDT - 2 years ago

Bioventus to Present at the Canaccord Genuity 43rd Annual Global Growth Conference

Aug 1, 2023, 5:35 PM EDT - 2 years ago

Bioventus to Report Second Quarter of Fiscal Year 2023 Financial Results on August 8, 2023

Jun 28, 2023, 2:18 PM EDT - 2 years ago

Bioventus: Return Of The King

May 23, 2023, 7:30 AM EDT - 2 years ago

Bioventus Completes Divestiture of its Wound Business

May 16, 2023, 10:53 PM EDT - 2 years ago

Bioventus Inc. (BVS) Q1 2023 Earnings Call Transcript

May 15, 2023, 5:33 PM EDT - 2 years ago

Bioventus Reschedules Reporting of First Quarter Fiscal Year 2023 Financial Results to After Market Close on May 16, 2023

May 11, 2023, 7:00 AM EDT - 2 years ago

Bioventus Reschedules Earnings Call to May 16, 2023; Files for Extension to File Form 10-Q for the Period Ended April 1, 2023

May 10, 2023, 9:00 AM EDT - 2 years ago

Bioventus Announces Divestiture of its Wound Business

May 3, 2023, 8:30 AM EDT - 2 years ago

Bioventus to Report First Quarter of Fiscal Year 2023 Financial Results on May 11, 2023

MrTicker Jul. 30 at 2:33 PM

0 · Reply

MrTicker Jul. 30 at 2:06 PM

$BVS volume slowly picking up.. about to break through $7+ on news

0 · Reply

BigSqueezeComing Jul. 30 at 11:48 AM

$BVS MarketBeat (4 analysts): $13.75 average, ranging from $12.00 to $15.00, implying approximately 110% upside from the $6.53 share price as of July 28, 2025 .

0 · Reply

BigSqueezeComing Jul. 30 at 11:47 AM

$BVS The peripheral nerve stimulation market is growing over 20% annually and is projected to exceed $500 million by 2029

0 · Reply

MrTicker Jul. 30 at 11:46 AM

$BVS excellent news...word not out yet

0 · Reply

BigSqueezeComing Jul. 30 at 11:45 AM

$BVS Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products By Bioventus, Inc. | July 30, 2025, 7:30 AM

0 · Reply

StockRedBaron Jul. 30 at 11:42 AM

$BVS WOW! So HUGE for us!...WHY all the Insider Buying in June!! https://finance.yahoo.com/news/bioventus-receives-fda-510-k-113000698.html

0 · Reply

MrTicker Jul. 30 at 11:39 AM

0 · Reply

MrTicker Jul. 30 at 11:33 AM

$BVS Bioventus Receives FDA 510(k) Clearances for two Next-Generation Peripheral Nerve Stimulation Products GLOBENEWSWIRE 6:30 AM ET 7/30/2025

0 · Reply

swingingtech Jun. 20 at 12:08 PM

$FHLC $BVS $BCRX $AVBP https://wallstreetwaves.com/peek-under-the-hood-fhlc-has-21-upside/

0 · Reply

TheLearnerEarner May. 30 at 2:11 PM

$BVS ✅ Healthcare - Mid Cap - F-Score: 6/9 Analysts: 2x buy rating 👨‍🔬 Intrinsic Value Potential: Excellent 💎 RSI: 39.23 (oversold bullish) 📊🐂 Highest Analysts Price Target: $15.00 (130% above Price) 🌟 Range (12m) $5.28 - $14.38 💰 Positive Free Cash Flow: Yes 🏧 NEWSDESK (last recent article) 📰 https://www.stocktitan.net/news/BVS/bioventus-reports-first-quarter-financial-uudx27wc3fec.html

0 · Reply

11thestate May. 16 at 12:17 PM

$BVS agreed to a $15.25M settlement with investors over claims it misled them about unexpected refund claims and financial reporting issues. Who’s eligible? Anyone who bought and held $BVS stock between February 11, 2021 and November 21, 2022. Do I need to sell to qualify? No — you're eligible if you bought during that period, even if you still hold the shares. How much is the payout? Estimated at $0.49 per share — but if only 25% of eligible investors file, it could go up to $1.96 per share. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Usually 8–12 months after the court grants final approval. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit

0 · Reply

11thestate May. 16 at 11:52 AM

$BVS agreed to a $15.25M settlement with investors over claims it misled them about unexpected refund claims and financial reporting issues. Who’s eligible? Anyone who bought and held $BVS stock between November 21, 2022 and December 2, 2024. Do I need to sell to qualify? No — you're eligible if you bought during that period, even if you still hold the shares. How much is the payout? Estimated at $0.49 per share — but if only 25% of eligible investors file, it could go up to $1.96 per share. Can I still file? Yes — late claims are currently being accepted. When do payouts happen? Usually 8–12 months after the court grants final approval. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit

0 · Reply

11thestate May. 9 at 12:14 PM

$BVS agreed to a $15.25M settlement with investors over claims it hid unexpected refund demands and financial issues tied to lower average selling prices. Who’s eligible? Anyone who bought and held $BVS stock between February 11, 2021 and November 21, 2022. Do I need to sell my shares to qualify? No — you're eligible if you purchased during that period, regardless of whether you sold or still hold. How much is the payout? Estimated at $0.49 per share, depending on how many investors file. Can I still file? Yes — late claims are currently being accepted, subject to court approval. When do payouts happen? Usually 8–12 months after final approval. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit

0 · Reply

PenkeTrading May. 7 at 11:54 AM

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Bioventus Inc. Is that bullish or bearish? $BVS #Bioventus #RsiOversold #NASDAQ

0 · Reply

11thestate May. 2 at 12:14 PM

$BVS agreed to a $15.25M settlement with investors over claims it hid financial issues like unexpected refund demands and pricing problems. Who’s eligible? Anyone who bought $BVS stock between February 11, 2021 and November 21, 2022. Do I need to sell my shares to qualify? No — you're eligible if you purchased during that period, even if you still hold or already sold. How much is the payout? Estimated at $0.49 per share, but if only 25% of investors file, it could go up to $1.96 per share. Can I still file? Yes — late claims are currently being accepted, subject to court approval. When do payouts happen? Typically 8–12 months after final court approval (scheduled for December 13, 2024). To file your claim: https://11th.com/cases/bioventus-investor-lawsuit

0 · Reply

11thestate Apr. 25 at 12:01 PM

$BVS agreed to a $15.25M settlement with investors over claims related to unexpected refund claims and financial reporting issues. Who’s eligible? Anyone who purchased or otherwise acquired Bioventus ($BVS) common stock between February 11, 2021 and November 21, 2022. Do I need to sell my shares to qualify? No — you’re eligible even if you still hold the shares, as long as you bought during the class period. How much is the payout? Estimated at $0.49 per share, depending on the number of valid claims submitted. Can I still file? Yes — late claims are being accepted, subject to court approval. When will payments go out? Payouts usually happen 8–12 months after the final approval hearing. To file your claim: https://11th.com/cases/bioventus-investor-lawsuit

0 · Reply

GufusDumbledork Apr. 13 at 12:21 AM

$ZETA it’s a frivolous lawsuit and how do we know because one of the plaintiffs (Jae Hyung Jung) recently filed a similar lawsuit against $BVS

0 · Reply

11thestate Apr. 11 at 12:07 PM

$BVS has agreed to a $15.25M settlement with investors to resolve claims related to financial issues, including unexpected refund claims from customers. Even if you missed the deadline, if you bought $BVS between February 11, 2021, and November 21, 2022, you still can file for payment here: https://11th.com/cases/bioventus-investor-lawsuit

0 · Reply

11thestate Apr. 4 at 10:25 AM

0 · Reply

11thestate Mar. 28 at 11:20 AM

0 · Reply

NVDAMillionaire Mar. 23 at 4:23 AM

$BVS Digging BVS medical tech strategy. Pain treatments and surgical solutions look promising. Might add to portfolio on next dip. Watching closely. noteworthy article: https://beyondspx.com/article/bioventus-inc-bvs-a-global-leader-driving-innovation-for-active-healing

0 · Reply

Market Cap	568.44M
Revenue (ttm)	573.28M
Net Income (ttm)	-33.54M
EPS (ttm)	N/A
PE Ratio	13.84
Forward PE	14.57
Profit Margin	-5.85%
Debt to Equity Ratio	1.70

Volume	522,000
Avg Vol	459,210
Day's Range	N/A - N/A
Shares Out	82.14M
Stochastic %K	97%
Beta	0.83
Analysts	Strong Sell
Price Target	$12.75